Jeffrey C. Kern - Concepedia

Author

Jeffrey C. Kern

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

J. Kern, J.C. Kern, Jeffrey C. Kern, Jeffrey Kern

Publications

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Women's Health Research Institute Ambrx (United States)Pfizer (United States)Torrey Pines Institute For Molecular Studies

About

Jeffrey C. Kern is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	528
2	Natural Sciences	3	3	261
3	Biochemistry	2	2	236
4	Cell Biology	1	1	124
5	Chemical Biology	1	1	25

Jeffrey C. Kern

Publications

Citations

H-Index

Page 1

	Year	Citations
Design, Synthesis, and SAR of New Pyrrole-Oxindole Progesterone Receptor Modulators Leading to 5-(7-Fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1<i>H</i>-indol-5-yl)-1-methyl-1<i>H</i>-pyrrole-2-carbonitrile (WAY-255348) Andrew Fensome, William R. Adams, Andrea L. Adams, Journal of Medicinal Chemistry Molecular PharmacologyMedicinal ChemistryPr AntagonistProgesterone ReceptorBiochemistry	2008	196
Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody–Drug Conjugates Jeffrey C. Kern, Mark T. Cancilla, Deborah Dooney, Journal of the American Chemical Society	2016	136
A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation Peter V.N. Bodine, Barbara Stauffer, Helga Ponce‐de‐Leon, Bone SclerostinSignal TransductionBone Morphogenic ProteinWnt AntagonistMedicine	2009	124
Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation Chuan Hong, Noel Byrne, Beata Zamlynny, Nature Communications	2021	116
Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs Jeffrey C. Kern, Deborah Dooney, Rena Zhang, Bioconjugate Chemistry	2016	89
SAR studies of 6-aryl-1,3-dihydrobenzimidazol-2-ones as progesterone receptor antagonists Eugene A. Terefenko, Jeffrey C. Kern, Andrew Fensome, Bioorganic & Medicinal Chemistry Letters Progesterone Receptor AntagonistsMedicineMechanism Of ActionPharmacological AgentPharmacotherapy	2005	57
Development of Anti-CD74 Antibody–Drug Conjugates to Target Glucocorticoids to Immune Cells Philip E. Brandish, Anthony Palmieri, S. V. Antonenko, Bioconjugate Chemistry	2018	57
Modulation of Wnt Signaling Through Inhibition of Secreted Frizzled-Related Protein I (sFRP-1) with N-Substituted Piperidinyl Diphenylsulfonyl Sulfonamides William Moore, Jeffrey C. Kern, Ramesh A. Bhat, Journal of Medicinal Chemistry	2008	55
SAR studies of 6-(arylamino)-4,4-disubstituted-1-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-ones as progesterone receptor antagonists Jeffrey C. Kern, Eugene A. Terefenko, Andrew Fensome, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryProgesterone Receptor AntagonistsBiochemistryMedicineNatural Sciences	2006	40
Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia M. E. Layton, Jeffrey C. Kern, Timothy J. Hartingh, Journal of Medicinal Chemistry	2023	36

Page 1